UCB Pharma Overview
- Founded
-
1946
- Status
-
Acquired/Merged
- Employees
-
8,506
- Latest Deal Type
-
M&A
- Financing Rounds
-
2
- Investments
-
1
UCB Pharma General Information
Description
Developer and marketer of drugs. The company specializes in the research, development and market of drugs, pharmaceutical and biotechnological products.
Contact Information
Website
ucb.de
Formerly Known As
Schwarz Pharma AG
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Office
- Alfred-Nobel-Strasse 10
- 40789 Monheim
- Germany
+49 02173 000000
UCB Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
UCB Pharma Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer and marketer of drugs. The company specializes in the research, development and market of drugs, pharmaceutica
Pharmaceuticals
Monheim, Germany
8,506
As of 2011
0.000
0000-00-00
000000&0
000000
m ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incid
000000000000000
Mexico City, Mexico
0000
As of 0000
000.00
0000000 0000
000000
la pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui o
000000000000000
Tokyo, Japan
00000
As of 0000
00000000
Add Comparison
UCB Pharma Competitors (44)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Landsteiner Scientific | Private Equity-Backed | Mexico City, Mexico | 0000 | 000.00 | 0000000 0000 | |
| 00000000 000000 | Corporation | Tokyo, Japan | 00000 | 00000000 | ||
| 0000000 0000000000 | Corporation | Yilan City, Taiwan | 00 | |||
| 00000 | Corporation | Basel, Switzerland | 000000 | 00.000 | 00000000000 | 00.000 |
| 00000000 | Formerly VC-backed | Dublin, Ireland | 0000 | 00.000 | 000000000 | 00.000 |
UCB Pharma Patents
UCB Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220298112-A1 | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | Pending | 17-Jun-2019 | 0000000000 | |
| CA-3137091-A1 | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | Pending | 17-Jun-2019 | 0000000000 | |
| EP-3983384-A1 | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | Pending | 17-Jun-2019 | 0000000000 | |
| EP-3810587-A1 | Substituted alkoxypyridinyl indolsulfonamides | Active | 20-Jun-2018 | 0000000000 | |
| EP-3810587-B1 | Substituted alkoxypyridinyl indolsulfonamides | Active | 20-Jun-2018 | C07D401/12 |
UCB Pharma Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Eric Schemann | Geschäftsführung | ||
| Peter Mitterhofer | Geschäftsführung | ||
| Mark Mcdade | Chief Operating Officer |
UCB Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
UCB Pharma Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 22-Nov-2011 | 0000000000 | Drug Discovery |